Progetti FP7 coordinati da "Fundacio institut d'investigacio biomedica de bellvitge"
| # | ||||
|---|---|---|---|---|
| 1 | HDAC HEMATOPOIESIS Role of Class IIa Histone deacetylases in hematopoietic cell differentiation | 2007 | 100˙000.00 | 100˙000.00 |
| 2 | CANCEROMICS Modelling cancer in Caenorhabditis elegans | 2007 | 100˙000.00 | 100˙000.00 |
| 3 | RODCELL Cellular and molecular mechanisms of the light response in photoreceptor cells of the mammalian retina | 2008 | 100˙000.00 | 100˙000.00 |
| 4 | CANCERDIP The use of Methylated DNA Immunoprecipitation MeDIP in cancer for better clinical management | 2008 | 3˙922˙042.00 | 2˙999˙994.00 |
| 5 | PC INTERACTOME Assembly of a prostate cancer genome-wide molecular interactome for the identification of the key regulatory genes of malignant transformation and new targets for therapeutic intervention | 2010 | 241˙761.00 | 241˙761.00 |
| 6 | CURELUNG Determining (epi)genetic therapeutic signatures for improving lung cancer prognosis | 2011 | 3˙849˙117.00 | 2˙965˙749.00 |
| 7 | VIRAL&IMMUNE THERAPY Breaking Tolerance - Combination of Virotherapy and Immunotherapy for Cancer Treatment | 2011 | 153˙917.00 | 153˙917.00 |
| 8 | EPINORC Epigenetic Disruption of Non-Coding RNAs in Human Cancer | 2011 | 2˙497˙240.00 | 2˙497˙240.00 |
| 9 | MOAMAUX Modulation of AMPA receptor properties by auxiliary subunits | 2012 | 100˙000.00 | 100˙000.00 |
| 10 | DBA-CHECKPOINTS The Role of the RPL11/p53 Checkpoint in the Development and Treatment of DBA | 2012 | 100˙000.00 | 100˙000.00 |
| 11 | IT-LIVER STRATEGY TO INHIBIT TGF-Beta IN LIVER DISEASE | 2012 | 3˙312˙185.00 | 3˙312˙185.00 |
| 12 | EPIMIRMEL Crosstalk between microRNAs and epigenetics in melanocyte differentiation: A new approach to unravel the complexity of melanoma progression and metastasis | 2014 | 352˙176.00 | 352˙176.00 |
Altri progetti
L'Ente fundacio institut d'investigacio biomedica de bellvitge partecipato anche in questi progetti.
- HPV-AHEAD (2011, participant)
- ADVANCE (2012, participant)
- DEVELAGE (2012, participant)
- DEXLIFE (2012, participant)
- EPITRAIN (2013, participant)
- STATEGRA (2012, participant)
- VESSEL (2013, participant)
- TRANSLINK (2013, participant)
- TARGET-MELANOMA (2009, participant)
- DISCHROM (2009, participant)
- SYSKID (2010, participant)
- PREHDICT (2010, participant)
- IMMEEDIA (2010, participant)
- SYSCOL (2011, participant)
- HEPTROMIC (2010, participant)
- LEUKOTREAT (2010, participant)
- MABSOT (2010, participant)
- COLTHERES (2011, participant)
- EUROTARGET (2011, participant)
- EPINORC (2011, hostInstitution)
- EPINORC (2011, hostInstitution)
- CANCER THERAPIES (2011, participant)
- BLUEPRINT (2011, participant)